The Company’s technology concentration includes research and development on natural substances that can be used in foods, medical supplies, cosmetics and daily products. With this base technology, the Company succeeded in commercializing a 100% natural substance-based acaricide product for house dust mites, which is a major cause of allergic disease such as asthma, atopic dermatitis and allergic rhinitis.
‘Allerzero,’ the dust mite extermination product that the Company developed, has various advantages in terms of side-effects, cost-effectiveness and convenience of use compared to other synthetic acaricides or laborious exterminating methods such as special vaccuums or professional services. In addition, as people show increasing concern and unease regarding allergic diseases caused by vermin, Allerzero is expected to show tremendous growth and attract much attention worldwide.
Naturo Biotech has one registered patent in the US and two patents in Japan as well as 24 domestic patents. The Company has also filed 4 international patent (PCT) applications and 5 applications overseas, including the US, Brazil, Hong Kong and
Naturo Biotech Co., Ltd (‘Naturo Biotech’ or ‘the Company’), a biotechnology
venture company who’s major research field is natural substance development
from plant extracts and microbes, is seeking licensing-out partners for its natural
substance-based house dust mite exterminator.
Yong U KIM
Business Development Manager
Health Technology Transfer Center
KHIDI, provides various services on technology transfer. KHIDI will license and commercialise several technologies of KHIDI's client companies via collaboration with overseas partners.View profile
Clients in focus...